Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
Sponsor: GlaxoSmithKline
Listed as NCT01457924, this PHASE2 trial focuses on Multiple Sclerosis and remains completed. Sponsored by GlaxoSmithKline, it has been updated 10 times since 2011, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 5 earlier versions
-
Jul 2018 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Mar 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Nov 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Achim, Germany , Alzenau in Unterfranken, Germany , Atlanta, United States , Baracaldo/Vizcaya, Spain , Barcelona, Spain , Berlin, Germany , Bochum, Germany , Brno, Czechia , Castellon, Spain , Cologne, Germany and 40 more locations